Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1995-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/JCEM.80.11.7593417PMID 7593417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess.

  1995cited by this paper
• Expression cloning of the aldosterone target cell-specific 11 beta-hydroxysteroid dehydrogenase from rabbit collecting duct cells.

  1995cited by this paper
• Substitution of arginine-839 by cysteine or histidine in the androgen receptor causes different receptor phenotypes in cultured cells and coordinate degrees of clinical androgen resistance.

  1994cited by this paper
• NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney.

  1994cited by this paper
• The prismatic case of apparent mineralocorticoid excess.

  1994cited by this paper
• Defects in the HSD11 gene encoding 11β-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency

  1994cited by this paper
• Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme.

  1994cited by this paper
• 11 beta-Hydroxysteroid dehydrogenase activity in the renal target cells of aldosterone.

  1991cited by this paper
• NEW FINDINGS IN APPARENT MINERALOCORTICOID EXCESS

  1987cited by this paper
• Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess.

  1983cited by this paper
• A simple method for displaying the hydropathic character of a protein.

  1982cited by this paper
• A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol.

  1979cited by this paper
• Empirical predictions of protein conformation.

  1978cited by this paper
• An abnormality in steroid reductive metabolism in a hypertensive syndrome.

  1977cited by this paper
• Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension.

  1977cited by this paper
• Conformational properties of amino acid residues in globular proteins.

  1976cited by this paper
• Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins.

  1974cited by this paper
• Prediction of protein conformation.

  1974cited by this paper

• What can we learn from the history of steroid metabolites and the ongoing identification of novel biologically active steroid metabolites?

  2026cites this paper
• Apparent mineralocorticoid excess: comprehensive overview of molecular genetics

  2022influential citation
• Receptor Transduction Pathways Mediating Hormone Action

  2021cites this paper
• Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess.

  2021cites this paper
• Modulation of 11β-hydroxysteroid dehydrogenase functions by the cloud of endogenous metabolites in a local microenvironment: the glycyrrhetinic acid-like factor (GALF) hypothesis.

  2021cites this paper
• 11β-hydroxysteroid dehydrogenases: a growing multi-tasking family.

  2021cites this paper
• Tributyltin and triphenyltin induce 11β-hydroxysteroid dehydrogenase 2 expression and activity through activation of retinoid X receptor α.

  2020cites this paper
• Species-specific differences in the inhibition of 11β-hydroxysteroid dehydrogenase 2 by itraconazole and posaconazole.

  2020cites this paper
• Drug-induced endocrine blood pressure elevation.

  2020cites this paper
• Endocrine Hypertension

  2020cites this paper
• A comprehensive urinary steroid analysis strategy using two-dimensional gas chromatography - time of flight mass spectrometry.

  2018cites this paper
• Diagnostic approach to low‐renin hypertension

  2018cites this paper
• Virtual screening applications in short-chain dehydrogenase/reductase research.

  2017cites this paper
• Cortisol Metabolism as a Regulator of the Tissue-Specific Glucocorticoid Action

  2017cites this paper
• Cellular regulation of cortisol in vivo by 11-beta hydroxysteroid dehydrogenase type 1

  2017cites this paper
• Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency

  2017cites this paper
• Epigenetics and Arterial Hypertension

  2017cites this paper
• Screening for genetic variants implicated in monogenic forms of hypertension in a hypertensive urban black Free State cohort

  2016cites this paper
• Epigenetics and arterial hypertension: the challenge of emerging evidence.

  2015cites this paper
• Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases

  2015cites this paper
• Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature.

  2015cites this paper
• CHAPTER 3 - Receptor transduction pathways mediating hormone action

  2014cites this paper
• 11β-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis

  2013cites this paper
• Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine

  2013cites this paper
• Role of 11βHSD type 2 enzyme activity in essential hypertension and children with chronic kidney disease (CKD).

  2012cites this paper
• Virtual Screening as a Strategy for the Identification of Xenobiotics Disrupting Corticosteroid Action

  2012cites this paper
• Inherited forms of mineralocorticoid hypertension

  2011cites this paper
• Low-renin hypertension of childhood.

  2011cites this paper
• Herbal Medicine Containing Licorice May Be Contraindicated for a Patient with an HSD11B2 Mutation

  2011influential citation
• Adamantyl Ethanone Pyridyl Derivatives: Potent and Selective Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1

  2011cites this paper
• Discovery of Adamantyl Heterocyclic Ketones as Potent 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors

  2011cites this paper
• Katedra i Zakład Farmacji Fizycznej i Farmakokinetyki

  2011cites this paper
• Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans.

  2010cites this paper
• Endocrine hypertension: diagnosis and management of a complex clinical entity.

  2010cites this paper
• In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence.

  2010influential citation
• Functional Analysis of Sequence Variation In silico structure-function analysis of pathological variation in the HSD 11 B 2 gene sequence

  2010cites this paper
• Administration of glycyrrhetinic acid: significant correlation between serum levels and the cortisol/cortisone-ratio in serum and urine.

  2009cites this paper
• The Syndrome of Apparent Mineralocorticoid Excess

  2009cites this paper
• 4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.

  2008cites this paper
• Correlation of glycyrrhetinic acid-like factors (kidney 11beta-HSD2-GALFs) with urinary free cortisol and plasma renin activity in essential hypertension.

  2008cites this paper
• Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.

  2008cites this paper
• Mineralocorticoid effects due to cortisol inactivation overload explain the beneficial use of hydrocortisone in septic shock.

  2008cites this paper
• Rôles physiopathologiques des récepteurs corticostéroïdes dans le rein et dans l'endothélium vasculaire : apports des modèles conditionnels transgéniques

  2008cites this paper
• Research Article Correlation of glycyrrhetinic acid-like factors (kidney 11-HSD2- GALFs) with urinary free cortisol and plasma renin activity in essential hypertension

  2008cites this paper
• Phenylcyclobutyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.

  2008cites this paper
• CHAPTER 2 – Receptor Transduction of Hormone Action

  2008cites this paper
• Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

  2008cites this paper
• Renal interstitial corticosterone and 11‐dehydrocorticosterone in conscious rats

  2007cites this paper
• Metaboliczna otyłość u osób z prawidłową masą ciała

  2007cites this paper
• 11β-hydroxystéroïde déshydrogénases. Avancées récentes

  2007cites this paper
• Characterization of 11β-hydroxysteroid dehydrogenase activities in the renal cell line LLC-PK1

  2007cites this paper
• Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.

  2007cites this paper
• [11beta-hydroxysteroide dehydrogenases. Recent advances].

  2007cites this paper
• Endogenous inhibitors (GALFs) of 11β-hydroxysteroid dehydrogenase isoforms 1 and 2: Derivatives of adrenally produced corticosterone and cortisol

  2007cites this paper
• 11β-hydroxystéroïde déshydrogénases. Avancées récentes 11β-hydroxysteroide dehydrogenases. Recent advances

  2007cites this paper
• Cortisol metabolism in hypertension.

  2006cites this paper
• Proinflammatory cytokines inhibit human placental 11beta-hydroxysteroid dehydrogenase type 2 activity through Ca2+ and cAMP pathways.

  2006cites this paper
• Inflammation, local vascular glucocorticoid regulation and endothelial function

  2006cites this paper
• Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus.

  2006cites this paper
• 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action

  2005influential citation
• Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

  2005cites this paper
• . 11 (cid:1) -Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action

  2005cites this paper
• Endogenous selective inhibitors of 11β-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin

  2005cites this paper
• Monogenic low renin hypertension.

  2005cites this paper
• Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice.

  2005cites this paper
• 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.

  2005cites this paper
• Apparent Mineralocorticoid Excess Syndrome : An Overview Mario Palermo

  2005cites this paper
• CLINICAL CASE SEMINAR In Vitro Expression Studies of a Novel Mutation 299 in a Patient Affected with Apparent Mineralocorticoid Excess

  2004cites this paper
• Telomeres and coronary heart disease

  2004cites this paper
• In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess.

  2004cites this paper
• Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.

  2004cites this paper
• Apparent mineralocorticoid excess syndrome: an overview.

  2004cites this paper
• Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population.

  2004cites this paper
• revisão Apparent Mineralocorticoid Excess Syndrome: An Overview

  2004cites this paper
• Hypertension and the cortisol-cortisone shuttle.

  2003cites this paper
• Forms of mineralocorticoid hypertension.

  2003cites this paper
• The functional roles of 11β-HSD1: vascular tissue, testis and brain

  2003cites this paper
• Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease.

  2003cites this paper
• A genome-wide linkage analysis investigating the determinants of blood pressure in whites and African Americans.

  2003cites this paper
• Hypertension and adrenal disorders

  2003cites this paper
• 11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease

  2003cites this paper
• Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action.

  2003cites this paper
• The functional roles of 11 beta-HSD1: vascular tissue, testis and brain.

  2003cites this paper
• Pathophysiological roles of vascular 11beta-hydroxysteroid dehydrogenase and aldosterone.

  2003cites this paper
• Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure

  2003cites this paper
• Hypertension in Congenital Adrenal Hyperplasia and Apparent Mineralocorticoid Excess

  2002cites this paper
• 19-Noraldosterone in pregnancy-induced hypertension.

  2002cites this paper
• Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria.

  2002cites this paper
• The genetics of human hypertension.

  2002cites this paper
• Pathophysiology of adrenal hypertension.

  2002cites this paper
• Genetics of the mineralocorticoid system in primary hypertension

  2002cites this paper
• Genetic alterations in patients with primary aldosteronism.

  2001cites this paper
• Juvenile Hypertension, the Role of Genetically Altered Steroid Metabolism

  2001cites this paper
• artigo original O Espectro das Síndromes de Hipertensão Esteróide na Infância e Adolescência

  2001cites this paper
• The 11beta hydroxysteroid dehydrogenase 2 exists as an inactive dimer.

  2001cites this paper
• 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.

  2001cites this paper
• Apparent mineralocorticoid excess.

  2001cites this paper
• Insights Into Glucocorticoid-Associated Hypertension.

  2001cites this paper
• LACK OF MUTATIONS OF TYPE 1 11β-HYDROXYSTEROID DEHYDROGENASE GENE IN PATIENTS WITH ABDOMINAL OBESITY

  2001cites this paper
• 18 Cortisol Metabolism

  2001cites this paper